Peramivir Brand Name– Rapivab
What is Peramivir
Peramivir is an intravenous neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than 48 hours.
The efficacy is based on clinical trials in which the predominant influenza virus type was influenza A; only a limited number of patients infected with influenza B virus were enrolled.
Peramivir is not a substitute for annual influenza virus vaccination. Instead, antiviral drugs are considered adjuncts to the prevention and control of influenza; annual influenza vaccination remains the main option for reducing the impact of influenza.
An Emergency Use Authorization (EUA) was previously issued for peramivir in which the dosage regimen approved was a daily infusion for 5 to 10 days; however, the FDA-approved regimen is a single infusion for patients with uncomplicated influenza only.
An interim analysis of a phase 3 study failed to show a significant difference in efficacy of peramivir (5-day course) and standard of care vs. placebo and standard of care in patients with serious influenza requiring hospitalization.
Indications
- avian influenza A (H5N1) virus
- avian influenza A (H7N9) virus
- avian influenza A virus infection
- influenza A virus
- influenza A virus infection
- influenza B virus
- influenza B virus infection
Side Effects
- anaphylactoid reactions
- constipation
- delirium
- diarrhea
- elevated hepatic enzymes
- erythema
- erythema multiforme
- exfoliative dermatitis
- fever
- hallucinations
- hyperglycemia
- hypertension
- insomnia
- neutropenia
- proteinuria
- psychosis
- rash
- Stevens-Johnson syndrome
- vomiting
Monitoring Parameters
- CBC
- LFTs
- serum creatinine/BUN
- urinalysis
Contraindications
- breast-feeding
- children
- dialysis
- infants
- infection
- pregnancy
- psychosis
- renal failure
- renal impairment
- serious hypersensitivity reactions or anaphylaxis
- serious rash
Interactions
- Intranasal Influenza Vaccine
